We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Omthera Stockholders Approve Acquisition by AstraZeneca PR Newswire PRINCETON, N.J., July 16, 2013 PRINCETON, N.J., July 16, 2013 /PRNewswire/ -- The stockholders of Omthera Pharmaceuticals, Inc...
Omthera Pharmaceuticals Announces NDA Submission for Epanova™ for the Treatment of Patients with Very High Triglycerides PR Newswire PRINCETON, N.J., July 9, 2013 PRINCETON, N.J., July 9, 2013...
Omthera Pharmaceuticals Announces Termination Of Antitrust Waiting Period PR Newswire PRINCETON, N.J., June 27, 2013 PRINCETON, N.J., June 27, 2013 /PRNewswire/ -- Omthera Pharmaceuticals, Inc...
Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders PR Newswire PRINCETON, N.J., June 13, 2013 PRINCETON, N.J., June 13, 2013 /PRNewswire/...
LONDON--AstraZeneca PLC (AZN.LN) is buying closely held U.S. drugs company Pearl Therapeutics for up to $1.15 billion to strengthen its respiratory drug portfolio and restock a dwindling drugs...
NEW YORK, June 4, 2013 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors of Omthera Pharmaceuticals, Inc. ("Omthera" or the "Company") (Nasdaq:OMTH) of claims of breaches of fiduciary duty...
AstraZeneca PLC offers $12.70 per share to Omthera Pharmaceuticals shareholders
Omthera Pharmaceuticals, Inc. Stockholders Seeking More Money, Information in Buyout Should Contact Deans & Lyons Law Firm PR Newswire DALLAS, May 30, 2013 DALLAS, May 30, 2013 /PRNewswire/...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Omthera Pharmaceuticals, Inc. (“Omthera” or the “Company”) (Nasdaq:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions